Home
International Diabetes Federation Grant Supports Jordanian Diabetes Micro-Clinic Program

International Diabetes Federation Grant Supports Jordanian Diabetes Micro-Clinic Program

May 28 2008 | comment(s)

BRUSSELS, Belgium and AMMAN, Jordan, May 29 /PRNewswire/ -- Over 250 million people worldwide live with diabetes, many in the Middle East. The International Diabetes Federation (IDF) BRIDGES translational research grant program is implementing and evaluating community programs to reverse the diabetes epidemic by supporting a diabetes awareness and prevention project in Jordan.

ComScore Acquires M:Metrics

ComScore Acquires M:Metrics

May 28 2008 | comment(s)

RESTON, Virginia, May 28 /PRNewswire/ --

- Acquisition Accelerates Expansion of comScore's Mobile Solutions, Cross Media Measurement and Global Footprint

comScore, Inc. (Nasdaq: SCOR), a leader in measuring the digital world, today announced the acquisition of M:Metrics, Inc., the recognized leader in mobile measurement. The acquisition makes comScore the immediate leader in measuring the emerging and strategically important mobile Internet market and adds to comScore's leading position in measuring PC-based Internet usage.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080115/COMSCORELOGO)

Pediatric Obesity Weighs Heavy On Society

Pediatric Obesity Weighs Heavy On Society

May 28 2008 | comment(s)

Do you ever get the feeling that science figures out a problem a few years after the fact, but then discovers that their methods for fixing the problem are also hopelessly outdated or just plain wrong, which puts us back another several years and at that point we may as well just give up and have wine with breakfast and hot fudge brownie sundaes for dinner? We know that Americans are fat. (If you don't believe me, look down - do you have a lap?) We also know that kids are getting fatter, which leads to a whole host of problems that will further tax our already overburdened health care system. Now, it seems as if maybe we're not getting fat as fast as we thought they were - although it could be a statistical aberration - and even if they are, we aren't sure if the diagnostic tools we have are relevant!
AMT Announces Presentations During The 11th Annual Meeting Of The ASGT

AMT Announces Presentations During The 11th Annual Meeting Of The ASGT

May 28 2008 | comment(s)

AMSTERDAM, May 28 /PRNewswire/ -- Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced today a series of presentations during the 11th Annual Meeting of the American Society of Gene Therapy in Boston, including a presentation on the pivotal clinical trial with its lead product AMT-011 on May 29.

About Amsterdam Molecular Therapeutics

Genmab Announces 2008 First Quarter Results

Genmab Announces 2008 First Quarter Results

May 28 2008 | comment(s)

COPENHAGEN, May 28 /PRNewswire/ --

- Summary: Genmab Reports Results for the First Three Months of 2008.

Genmab A/S (OMX: GEN) announced today results for the three month period ended March 31, 2008. During this period, Genmab reported the following results:

Genmab's revenues were DKK 167 million (approx. USD 36 million) for the first quarter of 2008. In the same period of 2007, Genmab recognized revenues of DKK 80 million (approx. USD 17 million).

An operating loss of DKK 197 million (approx. USD 42 million). This compares to an operating loss of DKK 106 million (approx. USD 22 million) reported for the corresponding period of 2007.

New Breast Cancer Scanner To Raise Quality Of Care For Women

New Breast Cancer Scanner To Raise Quality Of Care For Women

May 28 2008 | comment(s)

LONDON, May 28 /PRNewswire/ --

- New MRI System Under Development Could Potentially Lead to Diagnosis and Treatment in a Single Session

Breast cancer patients will receive faster treatment due to the development of a new, dedicated intra-operative magnetic resonance (MR) scanner which will enable doctors to carry out image-guided surgery as soon as problems are detected and diagnosed - possibly in a single out-patient session.

Highlights

PIERS Now Offers Argentine Import-Export Trade Data

PIERS Now Offers Argentine Import-Export Trade Data

May 28 2008 | comment(s)

NEWARK, New Jersey, May 28 /PRNewswire/ --

PIERS Global Intelligence Solutions, a Commonwealth Business Media company and the leading provider of U.S. trade data, has expanded its international import-export database resources to include current and historical data on Argentina's overland, water- and airborne cross-border commerce with the rest of the world.

"This is an important addition to our Latin American database, which now includes the top seven of the 12 South American national economies -- Brazil, Argentina, Colombia, Venezuela, Chile, Peru, and Ecuador -- as well as U.S.-NAFTA partner Mexico," explains Wael Jarous, vice president of PIERS Commercial Sales.

UK Businesses Lose GBP4 Billion A Year Due To Office 'e-break' Ban

UK Businesses Lose GBP4 Billion A Year Due To Office 'e-break' Ban

May 28 2008 | comment(s)

DUBLIN, May 28 /PRNewswire/ -- Banning personal internet use in the workplace could cost British businesses up to GBP4 billion every year* due to a resulting decline in staff productivity. That's according to a report, published today by PopCap.com that unveils research that indicates taking a 10-minute online break during the course of the working day serves to reduce stress while sharpening and refocusing the mind.

NICE Recommends Abbott's Adalimumab (HUMIRA(R)) For The Treatment Of Severe Active Ankylosing Spondylitis

NICE Recommends Abbott's Adalimumab (HUMIRA(R)) For The Treatment Of Severe Active Ankylosing Spondylitis

May 28 2008 | comment(s)

MAIDENHEAD, England, May 28 /PRNewswire/ --

- FOR IMMEDIATE RELEASE TO UK CONSUMER MEDIA ONLY

The National Institute for Health and Clinical Excellence (NICE) has today recommended adalimumab (HUMIRA) as one of the treatment options for people with severe active ankylosing spondylitis (AS),(1) a painful and progressive rheumatic disease.

This is the first time that NICE has reviewed anti-tumour necrosis factor (anti-TNF) therapies for AS. Today's decision is also the third positive opinion from NICE for adalimumab for rheumatological conditions, having been recommended for the treatment of active and progressive psoriatic arthritis and moderate-to-severe active rheumatoid arthritis in 2007.(2),(3)

Mechel Announces Its Victory In The Tender For The Right To Utilize The Subsoil Plot On The Uvatsk Quartzite Deposit

Mechel Announces Its Victory In The Tender For The Right To Utilize The Subsoil Plot On The Uvatsk Quartzite Deposit

May 28 2008 | comment(s)

IRKUTSK, Russia, May 28 /PRNewswire/ --

Mechel OAO (NYSE: MTL), one of the leading Russian mining and metals companies, announced that its Bratsk Ferroalloy Plant OOO subsidiary has won the tender to acquire the rights to utilize the subsoil plot on the Uvatsk deposit of quartzite and quartz sandstones.